RCS - Directa Plus PLC - Grant of EU Production Process Patent

Directa PlusAnnouncement

05/05/2021 07:05

RNS Number : 5389X
  
Directa Plus PLC
  
05 May 2021
  
 

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
 
5  May 2021
 
Directa Plus plc
("Directa Plus" or the "Company")
 
Grant of EU Production Process Patent
 
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has been granted an EU-wide patent covering the production process for its G+® graphene nanoplatelets.  The priority date for the patent is 20 June 2014.
 
The patent, titled 'Process for Preparing Graphene Nanoplatelets' covers the use of Directa Plus's unique water-based exfoliation technology for converting super-expanded graphite to pristine graphene nanoplatelets using no chemicals and with a very high conversion yield.  The process does not use any type of surfactant, organic solvent or acid and the Company's know-how allows the fine tuning of the exfoliation treatment to tailor the morphology of the graphene nanoplatelets according to customers' final application requirements.  This results in some significant advantages: G+® products are safe for human health due to the absence of chemistry, G+® graphene nanoplatelets can be tailor-made to partner requirements in different verticals and the high conversion yield delivers competitive prices.
 
Following the grant of the patent, Directa Plus's IP portfolio will comprise 16 patent families with 48 patents granted and 20 patents pending.
 
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "This grant means that our unique production process is now patented and that we have created a significant barrier to entry for competitors seeking to replicate our chemical-free technology.  We will continue to build our IP portfolio, covering both production technology and applications in order to continue to build value for shareholders."
 
For further information please visit http://www.directa-plus.com/ or contact:
 



Directa Plus plc


+39 02 36714458




Giulio Cesareo, CEO


 




Cenkos Securities plc (Nominated Adviser and Joint Broker)


+44 131 220 6939




Neil McDonald / Pete Lynch


 




N+1 Singer (Joint Broker)


+44 20 7496 3069




Rick Thompson / Phil Davies


 




Tavistock (Financial PR and IR)


+44 20 7920 3150




Simon Hudson / Edward Lee


 



 
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+® products) and, more recently, lithium-sulphur batteries.  In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products.  All our products are hypoallergenic, non-toxic and sustainably produced.
 
-ends-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRASSEFALEFSEII